Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SCB 2019

Next Previous
Drug Profile

SCB 2019

Alternative Names: 2019-nCoV S-Trimer vaccine - Clover Biopharmaceuticals; CpG-1018/Alum; Protein-based COVID-19 S-trimer vaccine - Clover Biopharmaceuticals; recombinant 2019-nCoV S protein subunit-trimer vaccine - Clover Biopharmaceuticals; Recombinant S subunit trimer vaccine - Clover Biopharmaceuticals; Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine - Clover Biopharmaceuticals; S-trimer COVID-19 vaccine; S-Trimer vaccine - Clover Biopharmaceuticals; SCB 2019 (CpG 1018/Alum); SCB-2019

Latest Information Update: 14 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clover Biopharmaceuticals
  • Class Adjuvants; COVID-19 vaccines; Recombinant proteins; Subunit vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III COVID 2019 infections

Most Recent Events

  • 23 Apr 2023 Clover Biopharmaceuticals completes the phase II/III SPECTRA trial in COVID-2019 infections (Prevention) in Belgium, Germany, Brazil, Colombia, Philippines, and South Africa (IM) (NCT04672395)
  • 15 Dec 2022 Clover Biopharmaceuticals withdraws a phase II/III trial in COVID-2019 infections (Prevention, In infants, In neonates, In adolescents, In children) in Colombia (IM), during the EC submission process prior to the enrolment (NCT05193279)
  • 20 Sep 2022 Clover Biopharmaceuticals announces intention to submit NDA and MAA to WHO, NMPA and EMA for COVID-2019 infections in the second half of 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top